- TC BioPharm (OTC: TCBPY) secures a European patent for modified gamma delta T cell therapies.
- The patent targets microbial, oncological, and viral indications, enhancing TC BioPharm's IP portfolio.
- The company plans to implement the patent in specific European countries as part of their commercial strategy.
TC BioPharm (OTC: TCBPY), a clinical-stage biotechnology company, announced the grant of a significant patent from the European Patent Office for its modified gamma delta T cell therapies. This patent focuses on targeting microbial, oncological, and viral indications, thereby strengthening the company's intellectual property position in the development of allogeneic cell therapies.
According to CEO Bryan Kobel, this patent is critical as it addresses the issue of off-target recognition in modified cell therapies, which can pave the way for broader therapeutic applications while minimizing toxicity risks. The company is set to proceed with the patent process in select European countries, aligning with its existing commercial strategy.
TC BioPharm is a leader in the development of gamma-delta T cell therapies and has pioneered phase II/pivotal clinical studies in oncology. The company's focus on refining cell targeting is expected to enhance the efficacy and safety of therapies across multiple indications, including microbial, oncological, and viral diseases.
This advancement in their patent portfolio signifies a strategic move towards expanding the application of high-impact therapies within Europe, potentially bringing innovative treatment options to a wider array of patients.
